The concentration of human immunodeficiency virus type 1 (HIV-1) RNA in plasma is a critical marker for predicting disease progression (19, 20) and for monitoring the efficacy of antiretroviral drug therapy (7, 23) . The geographic dispersal of genetically diverse viral subtypes of HIV-1 requires the use of molecular-based assays capable of accurately measuring viral RNA concentrations independent of viral sequence or subtype. HIV-1 has been divided into three divergent phylogenetic groups. Group M is the prevalent group and is subdivided into at least nine subtypes (subtypes A to H and J) (15) . HIV-1 groups O and N are both highly divergent and rare (13, 15, 28) . First-generation viral RNA quantitation tests were designed for optimal performance with subtype B, which initially predominated in North America and Europe. However, the entry of non-subtype B virus into these areas (1, 5, 6, 16) and the discovery of intersubtype recombinant viruses (18, 26) complicated nucleic acid-based testing (2, 11, 22, 24) . Moreover, there is a greater appreciation for the need to evaluate plasma HIV-1 RNA in other regions of the world. The inability of some molecular-based tests to efficiently quantitate viral RNA from non-B subtypes represents a significant problem for clinicians relying on viral RNA concentrations for monitoring antiretroviral drug therapy and for the design of preventive vaccine trials where viral RNA will be used as a clinical endpoint (14, 25) .
A previously described panel of 30 HIV-1 isolates of group M subtypes A through G (21) was used to assess the performance of six HIV-1 RNA quantitation tests: Roche Amplicor HIV-1 Monitor test (versions 1.0 and 1.5), Bayer Quantiplex HIV RNA (version 3.0), Digene Hybrid Capture II HIV RNA test (version 1.0), Organon Teknika NucliSens HIV QT test (version 2.0), and Gen-Probe HIV-1 Viral Load Assay (in development). The use of well-characterized viral stocks that are standardized by particle count allows for comparative analysis of the performance of HIV-1 RNA quantitation assays. Improved performance of the Roche Amplicor HIV-1 Monitor test, version 1.5, in the quantitation of A, E, F, and G subtypes was recently demonstrated with this panel (21, 27) .
Each member of the HIV-1 subtype panel was diluted into HIV-1-seronegative human plasma to deliver concentrations targeted at 50,000 to 100,000 RNA copies/ml based upon electron microscopic particle counts. Two different dilutions of the HIV-1 panel were used in this analysis because insufficient volume remained of the first dilution to allow for assessment of the Gen-Probe assay. In order to determine that the viral RNA target values were similar between the two dilutions, each viral dilution was retested by both versions of the Roche Amplicor HIV-1 Monitor tests (versions 1.0 and 1.5). Viral RNA values generated demonstrated that both dilutions of the panel gave similar viral RNA concentrations ( Table 1) . Aliquots of the diluted viral stocks were prepared and stored at Ϫ80°C. Vials of each viral isolate were thawed at room temperature for 30 min and vortexed vigorously for 10 s prior to removal for testing. All tests were performed following procedures recommended by the manufacturer of each test. Viral RNA quantitation results reported in this study represent values generated through singleton testing of each member of the HIV-1 subtype panel. Since viral RNA testing is not performed in replicate in a clinical testing laboratory, all tests were performed in singleton to generate data that reflected the type of data generated by clinical labs. Viral RNA testing was performed by laboratory staff having 2 or more years of experience in the performance of HIV-1 RNA quantitation assays. The laboratory's performance is routinely monitored by participation in Centers for Disease Control and Prevention MEPS or CAP HIV-1 RNA proficiency test panels for Roche Amplicor and Bayer Quantiplex assays.
Comparative quantitation results for both dilutions of the HIV-1 subtype panel members used in this study are summarized in Table 1 (21) . The high standard deviation observed for the Roche version 1.0 assay is indicative of the greater between-isolate variation for the Roche 1.0 assay than for the Roche 1.5, Gen-Probe, Bayer Quantiplex, and Digene assays. Standard deviations of 0.08 to 0.20 log 10 unit have been reported for three commercial HIV RNA quantitation kits using clinical specimens and spiked plasma, with clinical specimens having greater observed variability (4). In addition, a variability of 0.10 to 0.20 log 10 unit can be attributed to operator differences in the Roche Amplicor assay. A difference of 0.5 log 10 unit in RNA value is considered to be significant in the performance of viral RNA quantitation assays (17) . Table  2 shows the difference in log 10 -transformed RNA concentrations for the Roche Amplicor HIV-1 Monitor version 1.5 test and all other evaluated tests.
Three assays assessed in this report showed minimal differences between subtypes (Tables 1 and 2 Similar in performance to version 1.0 of the Roche Amplicor HIV-1 Monitor test, Organon Teknika's NucliSens HIV QT assay did not quantify subtypes E and F as efficiently. This assay, though, generated RNA values that were higher for E and F subtypes than the Roche Amplicor version 1.0 test. The mean log 10 differences were 0.49 (E) and 0.92 (F) for the NucliSens test compared to Roche Amplicor version 1.5. Mean log 10 differences of 1.18 (E) and 1.82 (F) were observed in the Roche Amplicor version 1.0 compared to version 1.5. The NucliSens test, though, quantified subtype A nearly as well as the Roche Amplicor version 1.5 test. Eight of the panel members had viral RNA values that were significantly lower (greater than 0.5 log 10 unit) that those generated by the Roche version 1.5 test. In addition, this assay could not detect the single G subtype isolate. These results are consistent with previously published data (8, 10) . A developmental modification of the NucliSens assay using primers from the long terminal repeat and pol regions that performs more uniformly across HIV-1 subtypes was recently reported but was not assessed for this analysis (10) .
The best comparative concentration values obtained were between version 1.5 of the Roche Amplicor HIV-1 Monitor test and the Gen-Probe Viral Load Assay (mean log 10 -unit difference of Ϫ0.02 [ Table 2 c Viral RNA values were generated using the second dilution for the subtype panel. d A value of 2.6 log 10 , which represents the lower detection limit of the assay, was used for subtype G in the calculation of the mean value for the NucliSens test. (3, 12) . The primers used in the Roche version 1.5 test (21) diverge extensively from group O RNA and would not be expected to efficiently amplify these sequences.
We show through the use of a panel of calibrated viral isolates that HIV-1 RNA quantitation tests developed or modified within the past 3 years are capable of quantifying a broader range of HIV-1 subtypes than tests which were developed earlier, when less information was available on the diversity of HIV-1 nucleic acid sequences. This improved performance reflects successful attempts by manufacturers to design HIV-1 viral RNA quantitation tests compatible with increasingly diverse HIV-1 subtypes. However, the process of test refinement must be continued, as the spread of the HIV-1 subtypes results in greater diversity and increased potential for lower efficiency of detection in viral RNA quantitation tests. With global migration of HIV-1 subtypes and recombination between all known HIV-1 group M subtypes, nucleic acidbased assays for the detection and quantitation of HIV-1 must be periodically monitored for their ability to detect and quantify prevalent HIV-1 subtypes.
